Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer.

Autor: Takahashi K; Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan., Uozumi R; Department of Industrial Engineering and Economics, Tokyo Institute of Technology, Tokyo, Japan., Mukohara T; Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan., Hayashida T; Department of Surgery, Keio University School of Medicine, Tokyo, Japan., Iwabe M; Department of Pharmacy, Miyagi Cancer Center, Miyagi, Japan., Iihara H; Department of Pharmacy, Gifu University Hospital, Gifu, Japan., Kusuhara-Mamishin K; Department of Pharmacy, National Cancer Center Hospital East, Chiba, Japan., Kitagawa Y; Department of Surgery, Keio University School of Medicine, Tokyo, Japan., Tsuchiya M; Department of Pharmacy, Miyagi Cancer Center, Miyagi, Japan., Kitahora M; Department of Pharmacy, Gifu University Hospital, Gifu, Japan., Nagayama A; Department of Surgery, Keio University School of Medicine, Tokyo, Japan., Kosaka S; Department of Surgery, National Hospital Organization Mito Medical Center, Ibaraki, Japan., Asano-Niwa Y; Department of Breast Surgery, Gifu University Hospital, Gifu, Japan., Seki T; Department of Surgery, Keio University School of Medicine, Tokyo, Japan., Ohnuki K; Department of Breast Surgery, Miyagi Cancer Center, Miyagi, Japan., Suzuki A; Department of Pharmacy, Gifu University Hospital, Gifu, Japan., Ono F; Department of Surgery, Keio University School of Medicine, Tokyo, Japan., Futamura M; Department of Breast Surgery, Gifu University Hospital, Gifu, Japan., Kawazoe H; Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan.; Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, Tokyo, Japan., Nakamura T; Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan.; Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, Tokyo, Japan.

Publikováno v: The oncologist [Oncologist] 2024 Jun 03; Vol. 29 (6), pp. e741-e749.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The impact of the COVID-19 pandemic on perioperative chemotherapy for breast cancer.

Autor: Baba K; Department of Pharmacy, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan., Kawamoto M; Department of Pharmacy, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan., Mamishin K; Department of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan., Uematsu M; Department of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan., Kiyohara H; Department of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan., Hirota A; Department of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan., Takahashi N; Department of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan., Fukuda M; Department of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan., Kusuhara S; Department of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan., Nakajima H; Department of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.; Department of Experimental Therapeutics, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan., Funasaka C; Department of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.; Department of Experimental Therapeutics, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan., Nakao T; Department of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.; Department of Experimental Therapeutics, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan., Kondoh C; Department of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan., Harano K; Department of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.; Department of Experimental Therapeutics, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan., Matsubara N; Department of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan., Naito Y; Department of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.; Department of Experimental Therapeutics, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.; Department of General Internal Medicine, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan., Hosono A; Department of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.; Department of Pediatric Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan., Kawasaki T; Department of Pharmacy, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan., Mukohara T; Department of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.

Publikováno v: Cancer medicine [Cancer Med] 2023 Jun; Vol. 12 (11), pp. 12095-12105. Date of Electronic Publication: 2023 Apr 03.

Patient-associated risk factors for severe anemia in patients with advanced ovarian or breast cancer receiving olaparib monotherapy: A multicenter retrospective study.

Autor: Tashiro R; Department of Pharmacy, National Cancer Center Hospital, Tokyo, Japan.; Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, Tokyo, Japan., Kawazoe H; Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, Tokyo, Japan.; Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan., Mamishin K; Department of Pharmacy, National Cancer Center Hospital East, Chiba, Japan., Seto K; Department of Pharmacy, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan., Udagawa R; Department of Pharmacy, National Cancer Center Hospital, Tokyo, Japan., Saito Y; Department of Pharmacy, National Cancer Center Hospital, Tokyo, Japan., Hashimoto H; Department of Pharmacy, National Cancer Center Hospital, Tokyo, Japan., Shimoi T; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Yonemori K; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Yonemura M; Department of Pharmacy, National Cancer Center Hospital East, Chiba, Japan., Terakado H; Department of Pharmacy, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan., Kawasaki T; Department of Pharmacy, National Cancer Center Hospital East, Chiba, Japan., Furukawa T; Department of Pharmacy, National Cancer Center Hospital, Tokyo, Japan., Nakamura T; Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, Tokyo, Japan.; Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan.

Publikováno v: Frontiers in oncology [Front Oncol] 2022 Oct 04; Vol. 12, pp. 898150. Date of Electronic Publication: 2022 Oct 04 (Print Publication: 2022).

The efficacy and safety of paclitaxel plus bevacizumab therapy in breast cancer patients with visceral crisis.

Autor: Funasaka C; Department of Medical Onology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa 277-8577, Japan., Naito Y; Department of Medical Onology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa 277-8577, Japan; Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan; Department of General Internal Medicine, National Cancer Center Hospital East, Kashiwa, Japan., Kusuhara S; Department of Medical Onology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa 277-8577, Japan., Nakao T; Department of Medical Onology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa 277-8577, Japan; Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan., Fukasawa Y; Department of Medical Onology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa 277-8577, Japan., Mamishin K; Department of Pharmacy, National Cancer Center Hospital East, Kashiwa, Japan., Komuro A; Department of Pharmacy, National Cancer Center Hospital East, Kashiwa, Japan., Okunaka M; Department of Pharmacy, National Cancer Center Hospital East, Kashiwa, Japan., Kondoh C; Department of Medical Onology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa 277-8577, Japan., Harano K; Department of Medical Onology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa 277-8577, Japan; Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan., Kogawa T; Department of Medical Onology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa 277-8577, Japan; Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan., Matsubara N; Department of Medical Onology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa 277-8577, Japan., Hosono A; Department of Medical Onology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa 277-8577, Japan; Department of General Internal Medicine, National Cancer Center Hospital East, Kashiwa, Japan., Kawasaki T; Department of Pharmacy, National Cancer Center Hospital East, Kashiwa, Japan., Mukohara T; Department of Medical Onology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa 277-8577, Japan. Electronic address: tmukohar@east.ncc.go.jp.

Publikováno v: Breast (Edinburgh, Scotland) [Breast] 2021 Aug; Vol. 58, pp. 50-56. Date of Electronic Publication: 2021 Apr 10.